Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anne Fuhlbrigge

Concepts (429)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Asthma
96
2024
2230
8.920
 Why?
Adrenal Cortex Hormones
27
2024
522
3.270
 Why?
Anti-Asthmatic Agents
27
2024
374
3.090
 Why?
Forced Expiratory Volume
19
2019
510
1.620
 Why?
Pulmonary Disease, Chronic Obstructive
11
2022
985
1.430
 Why?
Severity of Illness Index
20
2020
2742
1.020
 Why?
Administration, Inhalation
24
2024
666
0.940
 Why?
Anti-Inflammatory Agents
10
2016
480
0.910
 Why?
Lung Transplantation
10
2017
289
0.890
 Why?
Albuterol
5
2015
103
0.870
 Why?
Bronchodilator Agents
12
2016
243
0.840
 Why?
Budesonide
14
2016
89
0.820
 Why?
Nedocromil
11
2016
32
0.750
 Why?
Self Report
3
2023
799
0.730
 Why?
Humans
126
2025
129650
0.730
 Why?
Nasal Polyps
1
2021
59
0.720
 Why?
Endpoint Determination
2
2020
76
0.700
 Why?
Pharmacogenetics
2
2015
175
0.690
 Why?
Food Hypersensitivity
1
2022
176
0.650
 Why?
Sinusitis
1
2021
210
0.630
 Why?
Lung
7
2019
3930
0.620
 Why?
Virus Diseases
1
2021
211
0.610
 Why?
Physicians
2
2021
865
0.600
 Why?
Hospitalization
13
2020
2070
0.600
 Why?
Glucocorticoids
4
2022
575
0.590
 Why?
Remote Consultation
3
2025
47
0.590
 Why?
Symptom Assessment
1
2019
125
0.580
 Why?
Sleep Apnea, Obstructive
1
2021
275
0.550
 Why?
Oxygen Inhalation Therapy
4
2020
143
0.540
 Why?
Child
53
2022
20883
0.530
 Why?
Androstadienes
3
2012
106
0.530
 Why?
Emergency Service, Hospital
9
2013
1902
0.530
 Why?
Bone Density
2
2014
471
0.520
 Why?
Disease Progression
14
2020
2635
0.520
 Why?
Male
81
2024
63681
0.520
 Why?
Managed Care Programs
8
2008
133
0.510
 Why?
Precision Medicine
1
2020
387
0.510
 Why?
Adult
46
2024
35576
0.500
 Why?
Female
80
2024
68776
0.480
 Why?
Patient Reported Outcome Measures
1
2018
373
0.470
 Why?
Cost Savings
1
2015
78
0.470
 Why?
Practice Patterns, Physicians'
7
2020
1266
0.460
 Why?
Adrenergic beta-2 Receptor Agonists
4
2020
35
0.460
 Why?
Middle Aged
39
2024
31154
0.430
 Why?
Cost-Benefit Analysis
7
2022
569
0.420
 Why?
Peak Expiratory Flow Rate
2
2011
36
0.420
 Why?
Comorbidity
4
2021
1547
0.380
 Why?
Surveys and Questionnaires
14
2022
5406
0.370
 Why?
Adolescent
37
2019
20393
0.370
 Why?
Quality of Life
12
2023
2704
0.350
 Why?
Administration, Oral
6
2021
786
0.350
 Why?
Mentors
1
2012
178
0.350
 Why?
Medical Records Systems, Computerized
3
2008
93
0.350
 Why?
United States
23
2022
13903
0.340
 Why?
Respiratory Function Tests
10
2015
586
0.340
 Why?
Child, Preschool
31
2016
10517
0.330
 Why?
Medication Adherence
3
2023
558
0.330
 Why?
Faculty, Medical
1
2012
264
0.320
 Why?
Interprofessional Relations
3
2021
277
0.320
 Why?
Child Development
1
2014
457
0.320
 Why?
Spirometry
8
2020
257
0.320
 Why?
Treatment Outcome
15
2017
10230
0.310
 Why?
Aged
22
2022
22103
0.300
 Why?
Oxygen
3
2018
915
0.300
 Why?
Group Practice
1
2008
7
0.300
 Why?
Anti-Allergic Agents
2
2008
45
0.290
 Why?
Computer Simulation
1
2012
943
0.290
 Why?
Phenotype
5
2021
3076
0.280
 Why?
Dyspnea
3
2022
242
0.270
 Why?
Drug Utilization
4
2005
171
0.260
 Why?
Primary Health Care
5
2025
1680
0.260
 Why?
Follow-Up Studies
17
2017
4897
0.260
 Why?
Primary Graft Dysfunction
2
2017
29
0.260
 Why?
Quality Assurance, Health Care
1
2008
318
0.250
 Why?
Bronchiolitis Obliterans
3
2017
68
0.240
 Why?
Randomized Controlled Trials as Topic
7
2020
1368
0.240
 Why?
Gift Giving
1
2005
11
0.240
 Why?
Diagnostic Techniques, Respiratory System
1
2005
5
0.240
 Why?
Allergists
2
2022
12
0.240
 Why?
Respiratory Sounds
1
2006
118
0.240
 Why?
Genetic Testing
1
2008
428
0.240
 Why?
Delivery of Health Care
2
2021
894
0.230
 Why?
Cohort Studies
14
2013
5420
0.230
 Why?
Time Factors
10
2020
6556
0.220
 Why?
Antibodies, Monoclonal
2
2008
1367
0.220
 Why?
Leadership
2
2022
357
0.220
 Why?
Specialization
2
2025
145
0.220
 Why?
Natural Language Processing
1
2025
94
0.220
 Why?
Retrospective Studies
17
2022
14518
0.220
 Why?
Massachusetts
5
2016
159
0.220
 Why?
Medicine
1
2025
119
0.210
 Why?
Genetic Variation
1
2008
937
0.210
 Why?
Recurrence
5
2013
1007
0.210
 Why?
Rhinitis, Allergic, Perennial
1
2003
24
0.200
 Why?
Health Status
1
2008
755
0.200
 Why?
Steroids
8
2011
158
0.200
 Why?
Predictive Value of Tests
9
2012
1952
0.200
 Why?
Young Adult
11
2019
12426
0.200
 Why?
Multicenter Studies as Topic
4
2018
286
0.200
 Why?
Prevalence
4
2022
2564
0.190
 Why?
Beclomethasone
1
2022
27
0.190
 Why?
Models, Theoretical
4
2007
547
0.190
 Why?
Desensitization, Immunologic
1
2022
90
0.180
 Why?
Academic Medical Centers
2
2022
481
0.180
 Why?
Tiotropium Bromide
2
2018
19
0.180
 Why?
Nebulizers and Vaporizers
2
2020
83
0.180
 Why?
Biomarkers
3
2021
3973
0.180
 Why?
Patient Preference
1
2023
185
0.180
 Why?
Social Class
2
2022
257
0.180
 Why?
Churg-Strauss Syndrome
1
2020
25
0.170
 Why?
Electronic Health Records
2
2025
975
0.170
 Why?
Bronchoconstriction
3
2011
32
0.170
 Why?
Pulmonologists
1
2020
15
0.170
 Why?
Granulomatosis with Polyangiitis
1
2020
42
0.170
 Why?
Capacity Building
1
2021
59
0.170
 Why?
Muscarinic Antagonists
1
2020
27
0.170
 Why?
Agammaglobulinemia
1
2020
33
0.170
 Why?
Risk Factors
12
2018
9765
0.170
 Why?
Physician-Patient Relations
2
2021
539
0.170
 Why?
Practice Guidelines as Topic
5
2020
1501
0.160
 Why?
Air Pollution, Indoor
2
2002
140
0.160
 Why?
Treatment Adherence and Compliance
1
2019
24
0.160
 Why?
Exercise Test
1
2022
613
0.150
 Why?
Receptors, IgE
2
2009
44
0.150
 Why?
Prognosis
8
2017
3794
0.150
 Why?
Allergens
1
2021
385
0.150
 Why?
Emergency Medical Services
2
2007
522
0.140
 Why?
Vitamin D
2
2012
384
0.140
 Why?
Fossil Fuels
1
1997
8
0.140
 Why?
Alemtuzumab
1
2017
15
0.140
 Why?
Photopheresis
1
2017
9
0.140
 Why?
Hypersensitivity
1
2020
249
0.140
 Why?
Drug Prescriptions
2
2011
248
0.140
 Why?
Biological Products
1
2020
202
0.140
 Why?
Respiration
1
2017
191
0.130
 Why?
Respiration Disorders
1
1997
72
0.130
 Why?
Aged, 80 and over
6
2019
7086
0.130
 Why?
Physicians, Primary Care
3
2021
230
0.130
 Why?
Drug Combinations
3
2012
330
0.130
 Why?
Socioeconomic Factors
4
2022
1214
0.130
 Why?
Statistics, Nonparametric
1
2017
422
0.130
 Why?
Immunomodulation
1
2017
93
0.130
 Why?
Drug Therapy, Combination
5
2020
1040
0.130
 Why?
Patient Admission
1
2018
182
0.130
 Why?
Scopolamine Derivatives
1
2015
7
0.130
 Why?
Breath Tests
2
2008
91
0.130
 Why?
Immunoglobulin G
1
2020
847
0.120
 Why?
Embolism, Fat
1
2015
11
0.120
 Why?
Tobacco Smoke Pollution
2
2010
231
0.120
 Why?
Transplants
1
2015
35
0.120
 Why?
Cholinergic Antagonists
1
2015
29
0.120
 Why?
National Heart, Lung, and Blood Institute (U.S.)
1
2015
103
0.120
 Why?
Fluticasone-Salmeterol Drug Combination
2
2012
12
0.120
 Why?
Referral and Consultation
1
2021
732
0.120
 Why?
Genomics
2
2018
716
0.120
 Why?
Postoperative Complications
2
2017
2483
0.120
 Why?
Carcinoma, Bronchogenic
1
2015
19
0.120
 Why?
Longitudinal Studies
6
2017
2717
0.120
 Why?
Overweight
2
2011
531
0.120
 Why?
Telemedicine
1
2023
788
0.110
 Why?
Respiratory Tract Infections
2
2012
376
0.110
 Why?
Ambulatory Care Information Systems
2
2005
5
0.110
 Why?
Graft Rejection
2
2013
598
0.110
 Why?
Guideline Adherence
3
2020
526
0.110
 Why?
Prednisolone
1
2014
82
0.110
 Why?
Environmental Exposure
3
2006
462
0.110
 Why?
Risk
4
2015
854
0.110
 Why?
Education, Medical, Continuing
2
2005
122
0.110
 Why?
Quality Improvement
1
2022
1103
0.110
 Why?
Airway Obstruction
1
2015
152
0.110
 Why?
Forecasting
1
2015
359
0.100
 Why?
Bronchial Hyperreactivity
3
2010
105
0.100
 Why?
Transplantation
1
2013
31
0.100
 Why?
Office Visits
4
2011
85
0.100
 Why?
Insurance Claim Review
1
2013
64
0.100
 Why?
Medicare
2
2022
720
0.100
 Why?
Peer Group
2
2012
225
0.100
 Why?
Double-Blind Method
5
2010
1876
0.100
 Why?
Antibodies, Monoclonal, Humanized
2
2008
759
0.100
 Why?
Research
1
2015
416
0.100
 Why?
Growth
1
2012
58
0.100
 Why?
Cost of Illness
3
2003
278
0.100
 Why?
Costs and Cost Analysis
1
2013
201
0.100
 Why?
Methacholine Chloride
3
2008
51
0.100
 Why?
Cytomegalovirus Infections
2
2012
189
0.100
 Why?
Metered Dose Inhalers
1
2012
14
0.100
 Why?
Feedback
1
2012
162
0.100
 Why?
Drug Dosage Calculations
1
2011
22
0.100
 Why?
Mycoses
1
2012
71
0.100
 Why?
Logistic Models
5
2017
1988
0.090
 Why?
Antifungal Agents
1
2012
129
0.090
 Why?
Body Height
1
2012
193
0.090
 Why?
Effect Modifier, Epidemiologic
1
2011
13
0.090
 Why?
Professional Role
1
2012
158
0.090
 Why?
Multivariate Analysis
7
2017
1502
0.090
 Why?
Morbidity
2
2022
302
0.090
 Why?
Medication Errors
1
2012
95
0.090
 Why?
Obesity
3
2015
2883
0.090
 Why?
Epidemiologic Studies
1
2011
65
0.090
 Why?
Mycobacterium
1
2012
106
0.090
 Why?
Diagnostic Errors
1
2012
162
0.090
 Why?
Secondary Prevention
1
2012
218
0.090
 Why?
Patient Readmission
1
2016
667
0.090
 Why?
Pneumococcal Vaccines
1
2012
140
0.090
 Why?
Program Development
1
2012
357
0.090
 Why?
Lung Diseases
1
2017
742
0.090
 Why?
Drug Resistance
1
2011
166
0.090
 Why?
Vitamin D Deficiency
1
2012
176
0.080
 Why?
Probability
1
2011
306
0.080
 Why?
Ambulatory Care
2
2011
504
0.080
 Why?
Chi-Square Distribution
2
2017
516
0.080
 Why?
Decision Support Techniques
2
2012
396
0.080
 Why?
Bronchial Provocation Tests
2
2008
51
0.080
 Why?
Incidence
5
2020
2644
0.080
 Why?
Fluticasone
2
2008
90
0.080
 Why?
Algorithms
1
2017
1622
0.080
 Why?
Immunoglobulin E
2
2008
329
0.080
 Why?
Vital Capacity
4
2017
291
0.080
 Why?
Receptors, Corticotropin-Releasing Hormone
1
2009
27
0.080
 Why?
Lectins, C-Type
1
2009
71
0.080
 Why?
Proportional Hazards Models
1
2012
1201
0.080
 Why?
Cross-Sectional Studies
6
2010
5066
0.080
 Why?
Health Services
2
2007
99
0.080
 Why?
Health Knowledge, Attitudes, Practice
2
2012
1279
0.080
 Why?
Surgical Wound Infection
1
2012
283
0.080
 Why?
Pandemics
3
2022
1488
0.080
 Why?
Medication Therapy Management
1
2010
72
0.080
 Why?
Odds Ratio
4
2017
1023
0.080
 Why?
Smoking
3
2017
1501
0.080
 Why?
Kaplan-Meier Estimate
3
2016
857
0.080
 Why?
Acute Disease
1
2011
980
0.080
 Why?
Vitamin K Epoxide Reductases
1
2008
12
0.080
 Why?
Cytochrome P-450 CYP2C9
1
2008
20
0.080
 Why?
Eosinophil Cationic Protein
1
2008
10
0.080
 Why?
Mixed Function Oxygenases
1
2008
41
0.070
 Why?
Program Evaluation
1
2012
875
0.070
 Why?
Aryl Hydrocarbon Hydroxylases
1
2008
48
0.070
 Why?
Genetic Techniques
1
2008
63
0.070
 Why?
Genetic Predisposition to Disease
1
2016
2282
0.070
 Why?
Quality-Adjusted Life Years
2
2006
106
0.070
 Why?
Markov Chains
2
2006
117
0.070
 Why?
Trastuzumab
1
2008
101
0.070
 Why?
Insurance, Pharmaceutical Services
1
2008
23
0.070
 Why?
Cost Sharing
1
2008
14
0.070
 Why?
Adrenergic beta-Agonists
1
2008
132
0.070
 Why?
State Health Plans
1
2008
32
0.070
 Why?
Interviews as Topic
1
2011
717
0.070
 Why?
Smoking Cessation
1
2012
407
0.070
 Why?
Reimbursement Mechanisms
1
2008
84
0.070
 Why?
Chronic Disease
3
2017
1720
0.070
 Why?
Antibodies, Anti-Idiotypic
1
2007
57
0.070
 Why?
Health Services Accessibility
2
2021
902
0.070
 Why?
Warfarin
1
2008
147
0.070
 Why?
Exercise Tolerance
2
2022
273
0.070
 Why?
Mycobacterium Infections, Nontuberculous
1
2012
352
0.070
 Why?
Omalizumab
1
2007
50
0.070
 Why?
Factor Analysis, Statistical
1
2008
284
0.070
 Why?
Tomography, X-Ray Computed
1
2017
2535
0.070
 Why?
Databases, Factual
1
2012
1269
0.070
 Why?
Health Surveys
2
2006
494
0.070
 Why?
Antiviral Agents
1
2012
712
0.070
 Why?
Influenza Vaccines
1
2012
532
0.070
 Why?
Lung Diseases, Interstitial
1
2013
616
0.070
 Why?
Animals, Domestic
1
2006
14
0.070
 Why?
Receptor, ErbB-2
1
2008
326
0.060
 Why?
Biomedical Research
1
2012
638
0.060
 Why?
Eosinophils
1
2008
324
0.060
 Why?
Physicians, Family
2
2004
207
0.060
 Why?
Health Benefit Plans, Employee
1
2005
22
0.060
 Why?
Models, Biological
1
2012
1722
0.060
 Why?
Database Management Systems
1
2005
48
0.060
 Why?
Health Policy
1
2008
353
0.060
 Why?
Patients
1
2006
167
0.060
 Why?
Hip Fractures
1
2006
83
0.060
 Why?
Infant
3
2008
9024
0.060
 Why?
Insurance Coverage
1
2006
219
0.060
 Why?
Clinical Competence
1
2012
1017
0.060
 Why?
Body Mass Index
3
2015
2273
0.060
 Why?
Patient Education as Topic
3
2005
743
0.060
 Why?
Utilization Review
1
2004
36
0.060
 Why?
Mass Screening
1
2012
1149
0.060
 Why?
Prenatal Exposure Delayed Effects
1
2010
573
0.050
 Why?
Gene Expression Profiling
1
2011
1706
0.050
 Why?
Medicaid
1
2008
433
0.050
 Why?
Anticoagulants
1
2008
637
0.050
 Why?
Vaccination
1
2012
1348
0.050
 Why?
Sex Factors
3
2016
1968
0.050
 Why?
Attitude to Health
1
2006
431
0.050
 Why?
Anti-Bacterial Agents
2
2004
1717
0.050
 Why?
Circadian Rhythm
1
2006
413
0.050
 Why?
Clinical Trials as Topic
2
2005
1004
0.050
 Why?
Nitric Oxide
1
2008
902
0.050
 Why?
Parents
3
2006
1309
0.050
 Why?
Case Management
1
2003
64
0.050
 Why?
Choice Behavior
1
2004
165
0.050
 Why?
Puerto Rico
1
2022
52
0.050
 Why?
Symptom Flare Up
1
2022
38
0.050
 Why?
Lung Neoplasms
1
2015
2344
0.050
 Why?
Sputum
1
2004
302
0.050
 Why?
Academies and Institutes
1
2022
49
0.050
 Why?
Minority Groups
1
2003
249
0.050
 Why?
Health Services Research
1
2004
391
0.050
 Why?
Survival Rate
2
2016
1877
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2020
72
0.040
 Why?
Electronics
1
2021
75
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2020
93
0.040
 Why?
Sample Size
1
2020
116
0.040
 Why?
Efficiency
1
2021
91
0.040
 Why?
Health Care Reform
1
2021
101
0.040
 Why?
Schools, Medical
1
2021
132
0.040
 Why?
Risk Assessment
3
2020
3240
0.040
 Why?
Patient Selection
2
2020
663
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2020
62
0.040
 Why?
Patient Compliance
2
2016
565
0.040
 Why?
Language
1
2022
283
0.040
 Why?
Stress, Psychological
1
2007
1066
0.040
 Why?
Time
1
2019
75
0.040
 Why?
Cluster Analysis
2
2014
482
0.040
 Why?
Health Education
1
2002
334
0.040
 Why?
Quality of Health Care
1
2003
608
0.040
 Why?
Republic of Korea
1
2017
29
0.040
 Why?
Poland
1
2017
33
0.040
 Why?
Bronchitis, Chronic
1
2017
19
0.040
 Why?
Cooperative Behavior
1
2021
433
0.040
 Why?
Sensitivity and Specificity
3
2013
1838
0.040
 Why?
Patient-Centered Care
1
2003
505
0.040
 Why?
Nitrogen Dioxide
1
1997
32
0.030
 Why?
Long-Term Care
1
2018
92
0.030
 Why?
Geography
1
2018
188
0.030
 Why?
Pediatrics
1
2005
1052
0.030
 Why?
Self Concept
1
2019
242
0.030
 Why?
Antineoplastic Agents
1
2008
2061
0.030
 Why?
Aftercare
1
2019
205
0.030
 Why?
Monitoring, Physiologic
2
2012
268
0.030
 Why?
Netherlands
1
2016
77
0.030
 Why?
Tuberculosis, Pulmonary
1
2017
135
0.030
 Why?
Perception
1
2019
340
0.030
 Why?
Formoterol Fumarate
1
2015
7
0.030
 Why?
Feasibility Studies
1
2020
868
0.030
 Why?
Forced Expiratory Flow Rates
1
2015
14
0.030
 Why?
Ethanolamines
1
2015
17
0.030
 Why?
Salmeterol Xinafoate
1
2015
41
0.030
 Why?
Receptors, Adrenergic, beta-2
1
2015
46
0.030
 Why?
Treatment Failure
1
2016
340
0.030
 Why?
Self Efficacy
1
2019
374
0.030
 Why?
Dose-Response Relationship, Drug
2
2011
2012
0.030
 Why?
Education
1
2015
101
0.030
 Why?
Postoperative Period
1
2016
329
0.030
 Why?
Polymorphism, Single Nucleotide
2
2016
2073
0.030
 Why?
Age Factors
3
2008
3144
0.030
 Why?
Fatal Outcome
1
2015
300
0.030
 Why?
Immunosuppressive Agents
2
2015
853
0.030
 Why?
Pilot Projects
1
2020
1587
0.030
 Why?
Patient Acceptance of Health Care
1
2021
759
0.030
 Why?
Biopsy
2
2013
1097
0.030
 Why?
Combined Modality Therapy
1
2017
1206
0.030
 Why?
Gene Expression
1
2018
1472
0.030
 Why?
Telephone
2
2005
167
0.030
 Why?
Echinocandins
1
2012
7
0.030
 Why?
Lipopeptides
1
2012
13
0.030
 Why?
Tissue Donors
1
2015
391
0.030
 Why?
Amphotericin B
1
2012
29
0.020
 Why?
Aspergillosis
1
2012
20
0.020
 Why?
Intention to Treat Analysis
1
2012
68
0.020
 Why?
Candidiasis
1
2012
56
0.020
 Why?
Extracorporeal Membrane Oxygenation
1
2015
282
0.020
 Why?
Transplantation, Homologous
1
2013
401
0.020
 Why?
Hypoxia
1
2019
1084
0.020
 Why?
Mycobacterium avium Complex
1
2012
88
0.020
 Why?
Age Distribution
2
2003
372
0.020
 Why?
Cromolyn Sodium
2
2001
11
0.020
 Why?
Leukotriene Antagonists
1
2011
43
0.020
 Why?
Triazoles
1
2012
152
0.020
 Why?
Self Care
2
2005
370
0.020
 Why?
Functional Residual Capacity
1
2010
8
0.020
 Why?
Colorado
1
2021
4421
0.020
 Why?
Reference Values
1
2012
793
0.020
 Why?
Costa Rica
1
2010
16
0.020
 Why?
Principal Component Analysis
1
2011
189
0.020
 Why?
Nontuberculous Mycobacteria
1
2012
203
0.020
 Why?
Health
1
2010
74
0.020
 Why?
Genome-Wide Association Study
1
2016
1333
0.020
 Why?
Inhalation
1
2010
28
0.020
 Why?
Environment
1
2011
343
0.020
 Why?
Observation
1
2008
51
0.020
 Why?
Sex Ratio
1
2008
13
0.020
 Why?
Prospective Studies
2
2012
7133
0.020
 Why?
Least-Squares Analysis
1
2008
78
0.020
 Why?
Models, Econometric
1
2008
33
0.020
 Why?
Health Services Administration
1
2007
8
0.020
 Why?
Treatment Refusal
1
2008
89
0.020
 Why?
Social Isolation
1
2007
60
0.020
 Why?
Intelligence
1
2007
130
0.020
 Why?
Puberty
1
2008
143
0.020
 Why?
Body Weight
1
2011
940
0.020
 Why?
Child Behavior Disorders
1
2007
135
0.020
 Why?
Exercise
1
2016
1925
0.010
 Why?
Insurance, Health
1
2007
267
0.010
 Why?
CD4-Positive T-Lymphocytes
1
2011
1056
0.010
 Why?
Animals
1
2006
35361
0.010
 Why?
Genotype
1
2009
1839
0.010
 Why?
Bronchoconstrictor Agents
1
2003
16
0.010
 Why?
Health Status Indicators
1
2004
167
0.010
 Why?
Organizational Innovation
1
2004
139
0.010
 Why?
Case-Control Studies
1
2010
3381
0.010
 Why?
Systems Integration
1
2003
38
0.010
 Why?
Computer Systems
1
2003
44
0.010
 Why?
Motor Activity
1
2007
676
0.010
 Why?
Child Welfare
1
2004
211
0.010
 Why?
Histamine H1 Antagonists
1
2002
29
0.010
 Why?
Self Disclosure
1
2002
62
0.010
 Why?
Drug Administration Schedule
1
2004
769
0.010
 Why?
Administration, Intranasal
1
2002
84
0.010
 Why?
Confidence Intervals
1
2002
317
0.010
 Why?
Nurse's Role
1
2003
141
0.010
 Why?
Regression Analysis
1
2003
993
0.010
 Why?
Point-of-Care Systems
1
2003
147
0.010
 Why?
Health Care Surveys
1
2002
559
0.010
 Why?
Sex Distribution
1
2001
359
0.010
 Why?
Decision Support Systems, Clinical
1
2003
205
0.010
 Why?
Patient Satisfaction
1
2004
634
0.010
 Why?
Caregivers
1
2007
815
0.010
 Why?
Disease Management
1
2003
589
0.010
 Why?
Linear Models
1
2002
819
0.010
 Why?
Bronchoscopy
1
2000
216
0.010
 Why?
Internet
1
2003
617
0.010
 Why?
Pregnancy
1
2010
6402
0.010
 Why?
Survival Analysis
1
2000
1274
0.010
 Why?
Infant, Newborn
1
2004
5762
0.010
 Why?
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (429) concept(s)
_
Co-Authors Expand Description
See all (19) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)